Our objective was to determine the role of CTGF/CCN2 as a predictor of cardiovascular events in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT) cohort.
Immune cytokine TGF-β1 combined with cattle encephalon glycoside and ignotin injection could improve the contents of CTGF, HO-1 and NT-3, and be better to treat the peripheral neuropathy of type 2 diabetes.
Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.